BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27631382)

  • 21. Treatment of hepatitis B and C in children.
    El-Shabrawi M; Hassanin F
    Minerva Pediatr; 2014 Oct; 66(5):473-89. PubMed ID: 25253190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.
    Kim GA; Han S; Kim HD; An J; Lim YS
    J Viral Hepat; 2017 Nov; 24(11):990-997. PubMed ID: 28499070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of improved treatment on disease burden of chronic hepatitis C in New Zealand.
    Gane E; Stedman C; Brunton C; Radke S; Henderson C; Estes C; Razavi H
    N Z Med J; 2014 Dec; 127(1407):61-74. PubMed ID: 25530333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predicted effects of treatment for HCV infection vary among European countries.
    Deuffic-Burban S; Deltenre P; Buti M; Stroffolini T; Parkes J; Mühlberger N; Siebert U; Moreno C; Hatzakis A; Rosenberg W; Zeuzem S; Mathurin P
    Gastroenterology; 2012 Oct; 143(4):974-85.e14. PubMed ID: 22863764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of hepatitis C virus outside the liver: Evidence from Asia.
    Younossi ZM; Tanaka A; Eguchi Y; Lim YS; Yu ML; Kawada N; Dan YY; Brooks-Rooney C; Negro F; Mondelli MU
    Liver Int; 2017 Feb; 37(2):159-172. PubMed ID: 27748564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of emerging hepatitis C virus treatments on future needs for liver transplantation in France: a modelling approach.
    Deuffic-Burban S; Mathurin P; Rosa I; Bouvier AM; Cannesson A; Mourad A; Canva V; Louvet A; Deltenre P; Boleslawski E; Truant S; Pruvot FR; Dharancy S
    Dig Liver Dis; 2014 Feb; 46(2):157-63. PubMed ID: 24119483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
    Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
    Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
    Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term clinical benefits of Sofosbuvir-based direct antiviral regimens for patients with chronic hepatitis C in Central and West Africa.
    Baudoin M; Woode ME; Nishimwe ML; Lemoine M; Sylla B; Kouanfack C; Moh R; Seydi M; Rouveau N; Attia A; Lacombe K; Boyer S
    Liver Int; 2020 Nov; 40(11):2643-2654. PubMed ID: 32687669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward).
    Dore GJ; Ward J; Thursz M
    J Viral Hepat; 2014 May; 21 Suppl 1():1-4. PubMed ID: 24713003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors of unfavorable prognosis of chronic hepatitis C.
    Shchanitcyna SE; Burnevich EZ; Nikulkina EN; Filatova AL; Мoiseev SV; Мukhin NA
    Ter Arkh; 2019 Mar; 91(2):59-66. PubMed ID: 31094173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
    J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C.
    Lusivika-Nzinga C; Fontaine H; Dorival C; Simony M; Pol S; Carrat F;
    J Viral Hepat; 2019 Dec; 26(12):1489-1492. PubMed ID: 31386252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimating the impact of early hepatitis C virus clearance on hepatocellular carcinoma risk.
    Darvishian M; Janjua NZ; Chong M; Cook D; Samji H; Butt ZA; Yu A; Alvarez M; Yoshida E; Ramji A; Wong J; Woods R; Tyndall M; Krajden M
    J Viral Hepat; 2018 Dec; 25(12):1481-1492. PubMed ID: 30047609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Projecting future complications of chronic hepatitis C in the United States.
    Davis GL; Albright JE; Cook SF; Rosenberg DM
    Liver Transpl; 2003 Apr; 9(4):331-8. PubMed ID: 12682882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
    Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH
    J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis?
    Deuffic-Burban S; Boursier J; Leroy V; Yazdanpanah Y; Castera L; Mathurin P
    J Hepatol; 2017 Feb; 66(2):304-312. PubMed ID: 27743987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift.
    Aljumah AA; Abaalkhail F; Al-Ashgar H; Assiri A; Babatin M; Al Faleh F; Alghamdi A; Al-Hakeem R; Hashim A; Alqutub A; Razavi H; Sanai FM; Al-Swat K; Schmelzer J; Altraif I
    Saudi J Gastroenterol; 2016; 22(4):269-81. PubMed ID: 27488321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.